Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Helicin SCHEMBL9844557 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL20723406 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL9844555 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL988045 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL1006709 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL9888348 | 1.00 | SLC5A2 (0.57) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| SCHEMBL31064785 | 0.99 | SLC28A3 (0.55) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| Helicin SCHEMBL18864319 | 0.93 | SLC5A2 (0.54) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| SCHEMBL14120353 | 0.86 | HIF1A (0.54) | SLC5A2SLC28A3SLC5A1ATMTYR | |
| SCHEMBL16874167 | 0.86 | ATM (0.54) | SLC5A2SLC28A3SLC5A1ATMTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025095174-A1 | DEEP-FRIED AND BRAISED CHICKEN SAUCE WITH IMPROVED COLOR AND TEXTURE AND DEEP-FRIED AND BRAISED CHICKEN PREPARED BY USING SAME | 지병욱 | 2025-05-08 | — | — | WO | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| WO-2025073376-A1 | MASKING PREPARATIONS AND COMPOUNDS FROM DAEMONOROPS DRACO (DRAGON BLOOD) | SYMRISE AG (DE) | 2025-04-10 | — | — | WO | claimed |
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ROBERTS SUZANNAH JANE (US) | 2024-02-15 | — | — | US | claimed |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2020-08-13 | — | — | US | claimed |
| EP-3665180-A1 | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN ANAEROBIC CELLS AND RELATED CLINICAL METHODS FOR TREATING CANCER AND PATHOGENIC INFECTIONS | Cognate 3 LLC (US) | 2020-06-17 | — | — | EP | claimed |
| WO-2019032411-A1 | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN ANAEROBIC CELLS AND RELATED CLINICAL METHODS FOR TREATING CANCER AND PATHOGENIC INFECTIONS | COGNATE 3 LLC (US) | 2019-02-14 | — | — | WO | claimed |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2016-04-28 | — | — | US | claimed |
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | BROWN JOE ERNEST (US) | 2016-01-14 | — | — | US | claimed |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2012-10-04 | — | — | US | claimed |
| WO-2009145841-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | COGNATE 3, LLC (US) | 2009-12-03 | — | — | WO | claimed |
| EP-1337229-B1 | IMMOBILISATION OF ACTIVE AGENTS ON FIBRES | HENKEL AG & CO KGAA (DE) | 2009-09-30 | — | — | EP | claimed |
| US-20060248602-A1 | Bitter taste receptors | DEUTSCHES INSTITUT FUR ERNAHRUNGSFORSCHUNG (DE) | 2006-11-02 | — | — | US | claimed |
| EP-1543122-A2 | BITTER TASTE RECEPTORS | Deutsches Institut für Ernährungsforschung (DE) | 2005-06-22 | — | — | EP | claimed |
| WO-2004029087-A2 | BITTER TASTE RECEPTORS | Deutsches Institut für Ernährungsforschung (DE) | 2004-04-08 | — | — | WO | claimed |
| EP-0992277-B1 | Dry semipermeable reverse osmosis membrane and process for preparing the same using saccharides | SAEHAN IND INC (KR) | 2004-04-07 | — | — | EP | claimed |
| EP-1337229-A2 | IMMOBILISATION OF ACTIVE AGENTS ON FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-08-27 | — | — | EP | claimed |
| WO-2002043675-A2 | IMMOBILISATION OF ACTIVE AGENTS ON FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2002-06-06 | — | — | WO | claimed |
| EP-0992277-A1 | Dry semipermeable reverse osmosis membrane and process for preparing the same using saccharides | SAEHAN INDUSTRIES, INC. (KR) | 2000-04-12 | — | — | EP | claimed |
| US-4255319-A | PHOSPHINE INHIBITION; NONTOXIC; STORAGE STABILITY; MATERIALS HANDLING | UNION CARBIDE CORPORATION (US) | 1981-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | ICOS, IL2, NFATC1 | SLC5A2 3415/4885SLC28A3 4445/4885SLC5A1 3626/4885 |
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | SLC5A2 1011/4885SLC28A3 3379/4885SLC5A1 993/4885 |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | SLC5A2 3415/4885SLC28A3 4445/4885SLC5A1 3626/4885 |
| US-20060248602-A1 | Bitter taste receptors | TAS2R1, TAS2R30, TAS2R5 | SLC5A2 964/4885SLC28A3 1555/4885SLC5A1 769/4885 |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | ICOS, NFATC1, IL2 | SLC5A2 3588/4885SLC28A3 4547/4885SLC5A1 3975/4885 |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | SLC5A2 3415/4885SLC28A3 4445/4885SLC5A1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.